Gene therapy with gene delivery systems and therapeutic strategies: A new frontier in cancer treatment

被引:0
作者
Ramakrishnaiah, Thippenahalli Narasimhaiah [1 ]
Sowbhagya, Ramachandregowda [1 ]
Muktha, Harsha [1 ]
Surendra, Adagur Sudarshan [2 ]
Tanvi, Yesudas [1 ]
Srikar, Kalluri Surya [1 ]
Rajashekara, Somashekara [3 ]
机构
[1] MS Ramaiah Coll Arts Sci & Commerce, Dept Biotechnol & Genet, 7th Main Rd, Bengaluru 560054, Karnataka, India
[2] MS Ramaiah Coll Arts Sci & Commerce, Dept Biochem, 7th Main Rd, Bengaluru 560054, Karnataka, India
[3] Bangalore Univ, Ctr Appl Genet, Dept Studies Zool, Jnana Bharathi Campus,Off Mysuru Rd, Bengaluru 560056, Karnataka, India
关键词
Apoptosis; CRISPR/Cas9; Genetic engineering; Immunotherapy; Oncogenes; Viral vectors; DENDRITIC CELL VACCINATION; ZINC-FINGER NUCLEASES; NONVIRAL VECTORS; IMMUNE-RESPONSES; IN-VITRO; T-CELLS; CYTOSINE DEAMINASE; PROGENITOR CELLS; PROSTATE-CANCER; AAV VECTORS;
D O I
10.1016/j.jddst.2025.106798
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gene therapy is a cutting-edge approach in oncology, offering the promise of precise genetic manipulation within tumor cells to revolutionize cancer treatment paradigms. This review article delves into the sophisticated delivery systems-ranging from viral vectors such as adenoviruses and lentiviruses to emerging non-viral techniques like lipid nanoparticles-that enable the targeted introduction of therapeutic genes aimed at inducing apoptosis, inhibiting oncogenesis, and modulating immune responses. The potential for personalized gene therapy is explored, highlighting its role in tailoring treatments to individual tumor profiles and enhancing clinical outcomes while mitigating adverse effects. We examine recent breakthroughs, including CRISPR/Cas9 gene editing and oncolytic virus applications, which have shown substantial progress in preclinical models and early-phase trials, paving the way for improved survival rates across various malignancies. This comprehensive review covers critical aspects of current research: delivery mechanisms, therapeutic gene function, and design, personalization strategies, advancements in gene editing technologies, clinical trial findings, and anticipated challenges that future studies must address to optimize safety profiles and extend the applicability of gene therapy in oncological settings. The synthesis presented underscores the transformative potential of gene therapy as a targeted modality capable of fundamentally altering therapeutic landscapes, with personalized approaches serving as a cornerstone for its evolution into next-generation cancer treatments.
引用
收藏
页数:22
相关论文
共 283 条
  • [1] Advancements of gene therapy in cancer treatment: A comprehensive review
    Abas, Muhammad Dhiyauddin Mohd
    Asri, Muhammad Fareez Mohd
    Yusafawi, Nur Anis Suffiah
    Rosman, Nur Anis Zahra
    Baharudin, Nur Arifah Zahidah
    Taher, Muhammad
    Susanti, Deny
    Khotib, Junaidi
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2024, 261
  • [2] Interferons: role in cancer therapy
    Abdolvahab, Mohadeseh Haji
    Darvishi, Behrad
    Zarei, Mohammad
    Majidzadeh-A, Keivan
    Farahmand, Leila
    [J]. IMMUNOTHERAPY, 2020, 12 (11) : 833 - 855
  • [3] Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
    Adusumilli, Prasad S.
    Cherkassky, Leonid
    Villena-Vargas, Jonathan
    Colovos, Christos
    Servais, Elliot
    Plotkin, Jason
    Jones, David R.
    Sadelain, Michel
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (261)
  • [4] Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy
    Ahmadi, Seyed Esmaeil
    Soleymani, Maral
    Shahriyary, Fahimeh
    Amirzargar, Mohammad Reza
    Ofoghi, Mahya
    Fattahi, Mohammad Davood
    Safa, Majid
    [J]. CANCER GENE THERAPY, 2023, 30 (07) : 936 - 954
  • [5] Ajith T.A., 2015, J. Exp. Ther. Oncol., V11
  • [6] CAR-T cell combination therapy: the next revolution in cancer treatment
    Al-Haideri, Maysoon
    Tondok, Santalia Banne
    Safa, Salar Hozhabri
    Maleki, Ali Heidarnejad
    Rostami, Samaneh
    Jalil, Abduladheem Turki
    Al-Gazally, Moaed E.
    Alsaikhan, Fahad
    Rizaev, Jasur Alimdjanovich
    Mohammad, Talar Ahmad Merza
    Tahmasebi, Safa
    [J]. CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [7] Factors affecting the clearance and biodistribution of polymeric nanoparticles
    Alexis, Frank
    Pridgen, Eric
    Molnar, Linda K.
    Farokhzad, Omid C.
    [J]. MOLECULAR PHARMACEUTICS, 2008, 5 (04) : 505 - 515
  • [8] Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients
    Algazi, A.
    Bhatia, S.
    Agarwala, S.
    Molina, M.
    Lewis, K.
    Faries, M.
    Fong, L.
    Levine, L. P.
    Franco, M.
    Oglesby, A.
    Ballesteros-Merino, C.
    Bifulco, C. B.
    Fox, B. A.
    Bannavong, D.
    Talia, R.
    Browning, E.
    Le, M. H.
    Pierce, R. H.
    Gargosky, S.
    Tsai, K. K.
    Twitty, C.
    Daud, A. I.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (04) : 532 - 540
  • [9] Principles of CRISPR-Cas9 technology: Advancements in genome editing and emerging trends in drug delivery
    Aljabali, Alaa A. A.
    El-Tanani, Mohamed
    Tambuwala, Murtaza M.
    [J]. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 92
  • [10] Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management
    Allemailem, Khaled S.
    Alsahli, Mohammed A.
    Almatroudi, Ahmad
    Alrumaihi, Faris
    Alkhaleefah, Fahd Khaleefah
    Rahmani, Arshad Husain
    Khan, Amjad Ali
    [J]. CANCER COMMUNICATIONS, 2022, 42 (12) : 1257 - 1287